|
Gene: RAB11A |
Gene summary for RAB11A |
Gene summary. |
Gene information | Species | Human | Gene symbol | RAB11A | Gene ID | 8766 |
Gene name | RAB11A, member RAS oncogene family | |
Gene Alias | YL8 | |
Cytomap | 15q22.31 | |
Gene Type | protein-coding | GO ID | GO:0000070 | UniProtAcc | P62491 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
8766 | RAB11A | CA_HPV_1 | Human | Cervix | CC | 4.39e-05 | -1.31e-01 | 0.0264 |
8766 | RAB11A | N_HPV_1 | Human | Cervix | N_HPV | 2.49e-03 | -9.69e-02 | 0.0079 |
8766 | RAB11A | CCI_2 | Human | Cervix | CC | 7.53e-06 | 1.07e+00 | 0.5249 |
8766 | RAB11A | Tumor | Human | Cervix | CC | 2.58e-14 | 4.78e-01 | 0.1241 |
8766 | RAB11A | sample3 | Human | Cervix | CC | 3.38e-22 | 5.28e-01 | 0.1387 |
8766 | RAB11A | T3 | Human | Cervix | CC | 4.64e-22 | 5.65e-01 | 0.1389 |
8766 | RAB11A | HTA11_347_2000001011 | Human | Colorectum | AD | 2.28e-07 | 4.38e-01 | -0.1954 |
8766 | RAB11A | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.81e-03 | -1.98e-01 | 0.3005 |
8766 | RAB11A | A001-C-207 | Human | Colorectum | FAP | 1.35e-02 | -2.57e-01 | 0.1278 |
8766 | RAB11A | A015-C-203 | Human | Colorectum | FAP | 1.47e-16 | -3.05e-01 | -0.1294 |
8766 | RAB11A | A015-C-204 | Human | Colorectum | FAP | 3.09e-04 | -3.03e-01 | -0.0228 |
8766 | RAB11A | A002-C-201 | Human | Colorectum | FAP | 1.01e-09 | -3.26e-01 | 0.0324 |
8766 | RAB11A | A001-C-119 | Human | Colorectum | FAP | 1.50e-02 | -2.73e-01 | -0.1557 |
8766 | RAB11A | A001-C-108 | Human | Colorectum | FAP | 7.54e-15 | -3.29e-01 | -0.0272 |
8766 | RAB11A | A002-C-205 | Human | Colorectum | FAP | 9.06e-12 | -3.37e-01 | -0.1236 |
8766 | RAB11A | A001-C-104 | Human | Colorectum | FAP | 9.80e-06 | -2.65e-01 | 0.0184 |
8766 | RAB11A | A015-C-005 | Human | Colorectum | FAP | 3.18e-03 | -2.73e-01 | -0.0336 |
8766 | RAB11A | A015-C-006 | Human | Colorectum | FAP | 3.16e-09 | -4.14e-01 | -0.0994 |
8766 | RAB11A | A015-C-106 | Human | Colorectum | FAP | 2.86e-10 | -2.94e-01 | -0.0511 |
8766 | RAB11A | A002-C-114 | Human | Colorectum | FAP | 1.75e-11 | -3.97e-01 | -0.1561 |
Page: 1 2 3 4 5 6 7 8 9 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001063224 | Thyroid | HT | regulation of epithelial cell migration | 36/1272 | 292/18723 | 3.84e-04 | 4.84e-03 | 36 |
GO:000166728 | Thyroid | HT | ameboidal-type cell migration | 52/1272 | 475/18723 | 4.54e-04 | 5.53e-03 | 52 |
GO:199077825 | Thyroid | HT | protein localization to cell periphery | 39/1272 | 333/18723 | 6.29e-04 | 7.21e-03 | 39 |
GO:00507699 | Thyroid | HT | positive regulation of neurogenesis | 29/1272 | 225/18723 | 6.69e-04 | 7.61e-03 | 29 |
GO:001063126 | Thyroid | HT | epithelial cell migration | 41/1272 | 357/18723 | 6.87e-04 | 7.77e-03 | 41 |
GO:00972426 | Thyroid | HT | amyloid-beta clearance | 9/1272 | 38/18723 | 8.09e-04 | 8.78e-03 | 9 |
GO:009013226 | Thyroid | HT | epithelium migration | 41/1272 | 360/18723 | 8.11e-04 | 8.78e-03 | 41 |
GO:006156418 | Thyroid | HT | axon development | 50/1272 | 467/18723 | 9.50e-04 | 9.83e-03 | 50 |
GO:009013026 | Thyroid | HT | tissue migration | 41/1272 | 365/18723 | 1.06e-03 | 1.07e-02 | 41 |
GO:004505610 | Thyroid | HT | transcytosis | 6/1272 | 21/18723 | 2.17e-03 | 1.88e-02 | 6 |
GO:00512258 | Thyroid | HT | spindle assembly | 17/1272 | 117/18723 | 2.34e-03 | 2.00e-02 | 17 |
GO:00519627 | Thyroid | HT | positive regulation of nervous system development | 31/1272 | 272/18723 | 3.27e-03 | 2.58e-02 | 31 |
GO:003134619 | Thyroid | HT | positive regulation of cell projection organization | 38/1272 | 353/18723 | 3.34e-03 | 2.60e-02 | 38 |
GO:00903079 | Thyroid | HT | mitotic spindle assembly | 11/1272 | 65/18723 | 4.09e-03 | 2.99e-02 | 11 |
GO:001605016 | Thyroid | HT | vesicle organization | 33/1272 | 300/18723 | 4.30e-03 | 3.13e-02 | 33 |
GO:190307626 | Thyroid | HT | regulation of protein localization to plasma membrane | 15/1272 | 104/18723 | 4.41e-03 | 3.19e-02 | 15 |
GO:003253525 | Thyroid | HT | regulation of cellular component size | 40/1272 | 383/18723 | 4.50e-03 | 3.22e-02 | 40 |
GO:190437525 | Thyroid | HT | regulation of protein localization to cell periphery | 17/1272 | 125/18723 | 4.69e-03 | 3.28e-02 | 17 |
GO:004858818 | Thyroid | HT | developmental cell growth | 27/1272 | 234/18723 | 4.91e-03 | 3.35e-02 | 27 |
GO:005076715 | Thyroid | HT | regulation of neurogenesis | 38/1272 | 364/18723 | 5.56e-03 | 3.64e-02 | 38 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0414418 | Cervix | CC | Endocytosis | 64/1267 | 251/8465 | 6.97e-06 | 6.10e-05 | 3.61e-05 | 64 |
hsa0516414 | Cervix | CC | Influenza A | 43/1267 | 171/8465 | 3.03e-04 | 1.64e-03 | 9.68e-04 | 43 |
hsa0414419 | Cervix | CC | Endocytosis | 64/1267 | 251/8465 | 6.97e-06 | 6.10e-05 | 3.61e-05 | 64 |
hsa0516415 | Cervix | CC | Influenza A | 43/1267 | 171/8465 | 3.03e-04 | 1.64e-03 | 9.68e-04 | 43 |
hsa0516441 | Cervix | N_HPV | Influenza A | 16/349 | 171/8465 | 1.81e-03 | 1.12e-02 | 8.75e-03 | 16 |
hsa0516451 | Cervix | N_HPV | Influenza A | 16/349 | 171/8465 | 1.81e-03 | 1.12e-02 | 8.75e-03 | 16 |
hsa04144 | Colorectum | AD | Endocytosis | 111/2092 | 251/8465 | 5.95e-12 | 1.42e-10 | 9.08e-11 | 111 |
hsa04961 | Colorectum | AD | Endocrine and other factor-regulated calcium reabsorption | 24/2092 | 53/8465 | 8.49e-04 | 5.93e-03 | 3.78e-03 | 24 |
hsa04972 | Colorectum | AD | Pancreatic secretion | 36/2092 | 102/8465 | 1.06e-02 | 3.98e-02 | 2.54e-02 | 36 |
hsa041441 | Colorectum | AD | Endocytosis | 111/2092 | 251/8465 | 5.95e-12 | 1.42e-10 | 9.08e-11 | 111 |
hsa049611 | Colorectum | AD | Endocrine and other factor-regulated calcium reabsorption | 24/2092 | 53/8465 | 8.49e-04 | 5.93e-03 | 3.78e-03 | 24 |
hsa049721 | Colorectum | AD | Pancreatic secretion | 36/2092 | 102/8465 | 1.06e-02 | 3.98e-02 | 2.54e-02 | 36 |
hsa049724 | Colorectum | MSS | Pancreatic secretion | 33/1875 | 102/8465 | 1.09e-02 | 3.75e-02 | 2.30e-02 | 33 |
hsa049725 | Colorectum | MSS | Pancreatic secretion | 33/1875 | 102/8465 | 1.09e-02 | 3.75e-02 | 2.30e-02 | 33 |
hsa041446 | Colorectum | FAP | Endocytosis | 78/1404 | 251/8465 | 6.20e-09 | 2.96e-07 | 1.80e-07 | 78 |
hsa049726 | Colorectum | FAP | Pancreatic secretion | 34/1404 | 102/8465 | 2.43e-05 | 2.78e-04 | 1.69e-04 | 34 |
hsa049616 | Colorectum | FAP | Endocrine and other factor-regulated calcium reabsorption | 18/1404 | 53/8465 | 1.52e-03 | 7.94e-03 | 4.83e-03 | 18 |
hsa041447 | Colorectum | FAP | Endocytosis | 78/1404 | 251/8465 | 6.20e-09 | 2.96e-07 | 1.80e-07 | 78 |
hsa049727 | Colorectum | FAP | Pancreatic secretion | 34/1404 | 102/8465 | 2.43e-05 | 2.78e-04 | 1.69e-04 | 34 |
hsa049617 | Colorectum | FAP | Endocrine and other factor-regulated calcium reabsorption | 18/1404 | 53/8465 | 1.52e-03 | 7.94e-03 | 4.83e-03 | 18 |
Page: 1 2 3 4 5 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RAB11A | SNV | Missense_Mutation | novel | c.189G>C | p.Gln63His | p.Q63H | P62491 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.999) | TCGA-AO-A0J4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
RAB11A | SNV | Missense_Mutation | c.31C>T | p.Leu11Phe | p.L11F | P62491 | protein_coding | deleterious_low_confidence(0.01) | benign(0.105) | TCGA-AQ-A0Y5-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | SD | |
RAB11A | SNV | Missense_Mutation | rs759435629 | c.521N>A | p.Arg174His | p.R174H | P62491 | protein_coding | tolerated_low_confidence(0.31) | benign(0.001) | TCGA-A6-6141-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fu | SD |
RAB11A | SNV | Missense_Mutation | novel | c.158N>C | p.Ile53Thr | p.I53T | P62491 | protein_coding | deleterious_low_confidence(0.02) | possibly_damaging(0.519) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
RAB11A | SNV | Missense_Mutation | novel | c.382N>G | p.Leu128Val | p.L128V | P62491 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.822) | TCGA-AG-3887-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Chemotherapy | irinotecan | SD |
RAB11A | SNV | Missense_Mutation | novel | c.86C>A | p.Ser29Tyr | p.S29Y | P62491 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.711) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RAB11A | SNV | Missense_Mutation | novel | c.461N>T | p.Ser154Leu | p.S154L | P62491 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.994) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RAB11A | SNV | Missense_Mutation | novel | c.221G>A | p.Arg74Gln | p.R74Q | P62491 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.827) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
RAB11A | SNV | Missense_Mutation | c.386G>A | p.Arg129His | p.R129H | P62491 | protein_coding | deleterious_low_confidence(0.02) | benign(0.025) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
RAB11A | SNV | Missense_Mutation | novel | c.70N>C | p.Lys24Gln | p.K24Q | P62491 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.998) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |